[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Robinson LA: Solitary fibrous tumor of the pleura. Cancer Control; 2006 Oct;13(4):264-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura.
  • BACKGROUND: The solitary fibrous tumor of the pleura (SFTP) is a rare primary tumor arising from mesenchymal cells in the areolar tissue subjacent to the mesothelial-lined pleura.
  • The tumor appears to be unrelated to malignant pleural mesothelioma, the most common primary tumor of the pleura.
  • METHODS: In just over half of these cases, the neoplasm presents as an asymptomatic mass, is often quite large, and is benign in 78% to 88% of patients.
  • The initial evaluation and diagnosis, tumor classification, surgical treatment, results of therapy, and long-term prognosis are reviewed, based on a selective review of the literature from MEDLINE beginning 1980.
  • RESULTS: Complete en bloc surgical resection is the preferred treatment of benign and malignant varieties of the tumor.
  • The pedunculated tumors attached to the visceral pleura can be effectively treated with a wedge resection of lung.
  • CONCLUSIONS: Benign SFTP has a high cure rate and an 8% local recurrence rate that is usually amenable to curative re-excision.
  • The majority of patients with recurrent disease die of the tumor within 2 years.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Neoplasms, Fibrous Tissue / therapy. Pleural Neoplasms / diagnosis. Pleural Neoplasms / therapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Incidence. Neoadjuvant Therapy. Thoracic Surgical Procedures. Tomography, X-Ray Computed. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075563.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


2. Martínez Martínez P, Moldes Rodríguez M, Moreno Mata N, Simón Adiego C, Cebollero Presmanes M, González Aragoneses F: [Immunohistochemistry and surgical approaches in solitary fibrous tumor of the pleura]. Cir Esp; 2007 Mar;81(3):155-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemistry and surgical approaches in solitary fibrous tumor of the pleura].
  • [Transliterated title] Inmunohistoquímica y vías de abordaje en el tumor fibroso pleural.
  • Solitary fibrous tumor of the pleura (SFTP) is a rare, benign, slow-growing neoplasm that arises from the submesothelial cells of the pleura.
  • Usually, resection of the tumor and adjacent structures are sufficient for resolution.
  • CD34 antigen positivity is a differential feature with mesothelioma.
  • Only four patients were symptomatic at diagnosis.
  • Because of the malignant potential of this tumor, long-term follow-up is mandatory.
  • [MeSH-major] Neoplasms, Fibrous Tissue / immunology. Neoplasms, Fibrous Tissue / surgery. Pleural Neoplasms / immunology. Pleural Neoplasms / surgery. Thoracic Surgery, Video-Assisted / instrumentation
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / immunology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Mesothelioma / immunology. Mesothelioma / pathology. Mesothelioma / surgery. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349242.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


3. Ohar JA, Ampleford EJ, Howard SE, Sterling DA: Identification of a mesothelioma phenotype. Respir Med; 2007 Mar;101(3):503-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a mesothelioma phenotype.
  • Despite the strong association of asbestos exposure to mesothelioma, only a fraction of persons exposed develop this neoplasm which is characterized by long latency and shortened survival.
  • Familial clustering implicates both exposure and genetic predisposition as causative, but a biologically relevant mesothelioma phenotype essential to genetic analysis has not been defined.
  • To identify a more extensive set of traits that would define a mesothelioma phenotype for the purpose of genetic analysis, we set to determine characteristics that distinguish mesothelioma patients from others exposed to asbestos and to identify factors that predict the presence of mesothelioma over other mesenchymal tumors of the peritoneum and carcinoma metastatic to the pleura.
  • We compared demographics in four asbestos-exposed groups (controls n=347, bronchogenic cancer n=67, mesothelioma n=179 and benign asbestos-induced lung disease (BALD) n=3757).
  • Within the mesothelioma group, we compared traits to identify characteristics associated with shortened survival.
  • We found that compared to other asbestos-exposed groups, subjects with mesothelioma were younger at first asbestos exposure, had a greater risk of a second cancer diagnosis (odds ratio=3.29), had a longer disease latency, and had a greater risk of cancer among first-degree relatives (point estimate for risk 2.93; 95% CI 2.5-3.5).
  • Thoracic tumor location, work exposure and male gender were consistently associated with shortened survival (1.9+/-1.3 years).
  • We conclude that thoracic tumor location, work exposure, male gender, long latency, early age at first exposure, presence of a second cancer, and first-degree relative with cancer define a phenotype that sets mesothelioma patients with a short survival apart from other asbestos-exposed individuals.
  • [MeSH-major] Asbestos / adverse effects. Lung Neoplasms / genetics. Mesothelioma / genetics. Occupational Diseases / genetics
  • [MeSH-minor] Age Factors. Aged. Educational Status. Family Health. Female. Humans. Male. Middle Aged. Neoplasms, Multiple Primary. Occupational Exposure / adverse effects. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / mortality. Phenotype. Pleural Neoplasms / genetics. Pleural Neoplasms / mortality. Risk Factors. Sex Factors. Smoking / adverse effects


Advertisement
4. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res; 2007 May 15;13(10):2928-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
  • PURPOSE: Malignant mesothelioma is a highly aggressive tumor and is often diagnosed too late for a curative treatment.
  • We compared diagnostic and prognostic values of mesothelin and osteopontin in 172 patients suspected of malignant pleural mesothelioma (MPM) and in a control group of 112 asymptomatic asbestos-exposed subjects.
  • EXPERIMENTAL DESIGN: Osteopontin and mesothelin were assayed with commercial ELISA kits in a series of 43 patients with pleural metastases of various carcinomas, 33 patients with benign pleural lesions associated with asbestos exposure, 96 patients with MPMs, and 112 asbestos-exposed healthy subjects.
  • Results were correlated with patient's diagnosis and survival.
  • However, osteopontin was unable to distinguish between MPM and pleural metastatic carcinoma or benign pleural lesions associated with asbestos exposure.
  • Neither plasma nor pleural fluid osteopontin were more powerful in this respect.
  • Serum mesothelin had a good ability for diagnosing MPM but was unable to identify patients with nonepithelioid mesothelioma subtypes.
  • Survival analysis identified tumor histologic subtype along with serum osteopontin and serum mesothelin as independent prognostic factors in mesothelioma patients.
  • [MeSH-major] Membrane Glycoproteins / blood. Mesothelioma / diagnosis. Osteopontin / blood. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Aged. Extracellular Fluid / chemistry. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Pleura / chemistry. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504993.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


5. Liu J, He JX, Cai CJ, Chen HZ, Wei B, Shao WL, Li SB: [The analysis on the misdiagnosis of solitary fibrous tumor of the pleura]. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jun;33(6):432-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The analysis on the misdiagnosis of solitary fibrous tumor of the pleura].
  • OBJECTIVE: To report the characteristics of solitary fibrous tumor of the pleura (SFTP), and to analyze the factors associated with the misdiagnosis of this disease.
  • RESULTS: The preoperative diagnosis was pleural mesothelioma in 7 cases, neurogenic tumor in 6, lung cancer in 4, SFTP in 2, hilar lymph node tuberculosis in 1 and inflammatory granuloma in 1 case.
  • All the cases underwent radical resection, and postoperative pathology and immunohistochemical study were performed, and the diagnosis of benign solitary fibrous tumor of the pleura was confirmed.
  • CONCLUSION: The recognition of the clinical characteristics of pleural solitary fibrous tumor is essential for improving the diagnosis of this uncommon disease.
  • [MeSH-major] Diagnostic Errors. Pleural Neoplasms / diagnosis. Solitary Fibrous Tumor, Pleural / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979815.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW: Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax; 2007 Jul;62(7):569-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.
  • BACKGROUND: The diagnosis of malignant mesothelioma is frequently difficult, the most common differential diagnosis being reactive pleural conditions and metastatic adenocarcinoma.
  • Soluble mesothelin levels in serum have recently been shown to be highly specific and moderately sensitive for mesothelioma.
  • As most patients with mesothelioma present with exudative effusions of either the pleura or the peritoneum, a study was undertaken to determine if levels of mesothelin were raised in these fluids and if the increased levels could help to distinguish mesothelioma from other causes of exudative effusion.
  • METHODS: Pleural fluid was collected from 192 patients who presented to respiratory clinics (52 with malignant mesothelioma, 56 with non-mesotheliomatous malignancies and 84 with effusions of non-neoplastic origin).
  • Peritoneal fluid was collected from 42 patients (7 with mesothelioma, 14 with non-mesotheliomatous malignancies and 21 with benign effusions).
  • RESULTS: Significantly higher levels of mesothelin were found in effusions of patients with mesothelioma; with a specificity of 98%, the assay had a sensitivity of 67% comparing patients with mesothelioma and those with effusions of non-neoplastic origin.
  • In 7 out of 10 cases mesothelin levels were raised in the effusion collected 3 weeks to 10 months before the diagnosis of mesothelioma was made; in 4 out of 8 of these, mesothelin levels were increased in the effusion but not in the serum.
  • CONCLUSIONS: Measurement of mesothelin concentrations in the pleural and/or peritoneal effusion of patients may aid in the differential diagnosis of mesothelioma in patients presenting with effusions.
  • [MeSH-major] Membrane Glycoproteins / metabolism. Mesothelioma / diagnosis. Pleura / chemistry
  • [MeSH-minor] GPI-Linked Proteins. Humans. Pleural Effusion, Malignant / metabolism. Survival Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Nov;81(6):1059-65 [10576665.001]
  • [Cites] Cytopathology. 2000 Jun;11(3):139-51 [10877273.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):172-4 [17409849.001]
  • [Cites] Clin Biochem. 2000 Jul;33(5):405-10 [11018693.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):9-16 [11162861.001]
  • [Cites] Chest. 2001 Apr;119(4):1138-42 [11296181.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):192-7 [12640097.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):289-94 [12781427.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] Ann Intern Med. 1972 Oct;77(4):507-13 [4642731.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):373-81 [1735605.001]
  • [Cites] Lung. 1994;172(3):183-4 [8201832.001]
  • [Cites] Nephron. 1999;81(4):373-80 [10357643.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]
  • [Cites] Chest. 2004 Dec;126(6):1721-2 [15596661.001]
  • [Cites] Chest. 2004 Dec;126(6):1757-63 [15596670.001]
  • [Cites] Oncol Rep. 2005 Aug;14(2):357-62 [16012715.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] Oncologist. 2005 Aug;10(7):501-7 [16079317.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60 [16456138.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1014-20 [16702385.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1751 [16985043.001]
  • [CommentIn] Thorax. 2007 Jul;62(7):561-2 [17600291.001]
  • [CommentIn] Thorax. 2008 Jan;63(1):87-8; author reply 87 [18156575.001]
  • (PMID = 17356060.001).
  • [ISSN] 0040-6376
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  • [Other-IDs] NLM/ PMC2117248
  •  go-up   go-down


7. Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K: [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Pneumonol Alergol Pol; 2007;75(1):57-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
  • INTRODUCTION: Histopathological diagnosis of malignant mesothelioma (MM) and differentiating it from tumors infiltrating the pleura is very difficult.
  • Distinguishing benign reactive mesothelial cell proliferation from MM also presents problems.
  • The objective of this study was to evaluate the significance of selected immunohistochemical stains in differentiating MM from non-small cell lung cancers infiltrating the pleura and from benign reactive mesothelial cell proliferation.
  • MATERIAL AND METHODS: The material encompassed 86 cases of MM, 54 cases of NSCLC infiltrating the pleura, and 43 cases of benign reactive mesothelial cell proliferation.
  • It included broad-spectrum antibodies to cytokeratins (CKAE1/AE3, CKMNF116), vimentin, epithelial membrane antigen (EMA), mesothelial cells (HBME1, CK5/6, calretinin), adenocarcinoma cells (BerEp4, B72.3, CEA, TTF1), antibodies enabling the assessment of proliferation (Mib1) and cell-cycle regulating proteins (p53).
  • Non-small cell lung cancers infiltrating the pleura: Coexpression of cytokeratin and vimentin was found in 17.6% of the cases, positive staining of membranes for EMA, in 13% cases.
  • Benign reactive mesothelial cell proliferation: Protein p53 was present in 9.3% of cases, whereas no positive staining for EMA was found.
  • CONCLUSION: In diagnosing mesothelioma it is necessary to use a panel of immunohistochemical stains, which should contain antibodies to markers for adenocarcinoma and mesothelioma.
  • In the diagnosis of spindle-cell pleural tumors and the fibrous form of MM and benign reactive mesothelial cell proliferation , markers of mesothelial cells are noncontributory.
  • Immunohistochemical staining fails to identify a reactive process, but a diffuse, positive stain for EMA and the presence of protein p53 support the diagnosis of MM.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Mesothelioma / pathology. Neoplasm Proteins / analysis. Neoplasms, Mesothelial / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / analysis. Diagnosis, Differential. Epithelium / chemistry. Epithelium / pathology. Female. Humans. Hyperplasia / pathology. Immunohistochemistry. Lung / chemistry. Lung / pathology. Male. Middle Aged. Pleura / chemistry. Pleura / pathology. Pleural Effusion / chemistry. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541913.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


8. Chua TC, Yan TD, Morris DL: Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg; 2009 Feb;52(1):59-64
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.
  • Mesothelioma is an asbestos-related tumour.
  • Mesothelioma in the thorax occurs on the pleura and is known as pleural mesothelioma.
  • It is the more common form of mesothelioma, accounting for 70% of cases.
  • It accounts for much of the remaining 30% and is known as peritoneal mesothelioma.
  • Early diagnosis of peritoneal mesothelioma is often difficult because the early symptoms are often overlooked as being a benign ailment of the gastrointestinal tract.
  • Therefore, diagnosis often occurs at an advanced stage when disease is widespread throughout the peritoneal cavity.
  • We update on the current understanding of peritoneal mesothelioma from a clinical perspective in hope that greater clinician awareness will promote best practice management of this condition.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / therapy. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Asbestos / adverse effects. Biomarkers, Tumor. Chemotherapy, Cancer, Regional Perfusion. Diagnostic Imaging. Endoscopy, Gastrointestinal. Humans. Hyperthermia, Induced

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):515-25 [17031722.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):41-9 [17039392.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1105-13 [17206478.001]
  • [Cites] Ann Oncol. 2007 May;18(5):827-34 [17130182.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1807-17 [17342564.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2270-80 [17464543.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2047-52 [17434931.001]
  • [Cites] MedGenMed. 2007;9(2):32 [17955087.001]
  • [Cites] Br J Surg. 2007 Nov;94(11):1408-14 [17631678.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):125-33 [18030535.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):370-3 [18156144.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):136-47 [18227828.001]
  • [Cites] CMAJ. 2008 Mar 11;178(6):677-8 [18332380.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):181-8 [10618635.001]
  • [Cites] Br J Surg. 2000 Nov;87(11):1587-93 [11091251.001]
  • [Cites] J Clin Gastroenterol. 2001 Sep;33(3):247-50 [11500619.001]
  • [Cites] Am Surg. 2001 Oct;67(10):999-1003 [11603562.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):2-17 [11836664.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4169-75 [12154012.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):269-73 [12908781.001]
  • [Cites] Clin Lung Cancer. 2003 Nov;5(3):177-81 [14667274.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4560-7 [14673042.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S21-3 [15261428.001]
  • [Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):746-55 [7091938.001]
  • [Cites] Br J Ind Med. 1983 May;40(2):145-52 [6299326.001]
  • [Cites] Lancet. 1985 Nov 2;2(8462):977-81 [2414612.001]
  • [Cites] Acta Cytol. 1987 May-Jun;31(3):369-73 [3035848.001]
  • [Cites] Environ Res. 1987 Oct;44(1):103-16 [3115771.001]
  • [Cites] Am J Pathol. 1987 Dec;129(3):448-62 [2827488.001]
  • [Cites] Exp Pathol. 1987;32(3):129-52 [3436395.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(7):547-50 [1624547.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):792-8 [7850791.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Am J Physiol. 1995 Mar;268(3 Pt 1):L471-80 [7900829.001]
  • [Cites] Environ Health Perspect. 1994 Dec;102 Suppl 10:131-6 [7705288.001]
  • [Cites] Cancer Treat Res. 1996;82:359-74 [8849962.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5334-8 [8968079.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):53-8 [15642426.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):1-5 [15849996.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S3-8 [15950797.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Int J Occup Environ Health. 2005 Jul-Sep;11(3):254-8 [16130966.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):405-12 [16485159.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):41-5 [16767905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10397-402 [16798876.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1615-9 [16600983.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:871-81 [17119263.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):500-8 [17151789.001]
  • (PMID = 19234654.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1332-21-4 / Asbestos
  • [Number-of-references] 54
  • [Other-IDs] NLM/ PMC2637623
  •  go-up   go-down


9. Cagle PT, Churg A: Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med; 2005 Nov;129(11):1421-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
  • CONTEXT: Although much of the pathology literature focuses on differential diagnosis of diffuse malignant mesothelioma from other types of cancer, the primary diagnostic challenge facing the pathologist is often whether a mesothelial proliferation on a pleural biopsy represents a malignancy or a benign reactive hyperplasia.
  • DESIGN: Based on previous medical publications, extensive personal consultations, and experience on the United States-Canadian Mesothelioma Reference Panel and the International Mesothelioma Panel, salient information was determined about interpretation of benign versus malignant mesothelial proliferations on pleural biopsies.
  • RESULTS: Differentiation of benign reactive mesothelial hyperplasia from diffuse malignant mesothelioma is often difficult.
  • Benign reactive mesothelial hyperplasia may mimic many features ordinarily associated with malignancy, and diffuse malignant mesothelioma may be cytologically bland.
  • Entrapment of benign reactive mesothelial cells within organizing pleuritis may mimic tissue invasion.
  • CONCLUSIONS: Various histologic clues favor a benign over a malignant mesothelial proliferation and vice versa.
  • Invasion is the most reliable criterion for determining that a mesothelial proliferation is malignant.
  • When there is any doubt that a pleural biopsy represents a malignancy, we recommend a diagnosis of atypical mesothelial proliferation.
  • [MeSH-major] Epithelium / pathology. Mesothelioma / pathology. Pleura / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Hyperplasia / pathology. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253023.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


10. Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H: Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol; 2007 Dec;64(3):356-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and functional imaging of malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is an aggressive tumor that arises from the pleura and frequently extends to adjacent structures.
  • Major findings include nodular pleural thickening, unilateral pleural effusion, and tumor invasion of adjacent structures.
  • Because of its excellent contrast resolution, MRI is superior to CT, both in the differentiation of malignant from benign pleural disease, and in the assessment of chest wall and diaphragmatic involvement.
  • Perfusion MRI is the most promising technique for the assessment of the tumor microvasculature.
  • It has been shown that FDG-PET is useful for the differentiation of benign from malignant lesions, for staging and monitoring metabolic response to therapy against MPM, and that it has prognostic value.
  • An initial report on PET/CT imaging of MPM has shown increased accuracy of overall staging, improving the assessment of tumor resectability.
  • [MeSH-major] Diagnostic Imaging / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Humans. Magnetic Resonance Imaging / methods. Neoplasm Staging. Neovascularization, Pathologic / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954021.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 61
  •  go-up   go-down


11. Patel T, Bansal R, Trivedi P, Modi L, Shah MJ: Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):482-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report.
  • Metastasis of mesothelioma of the pleura, to the skin and subcutis is an extremely rare occurrence.
  • A 25 year old woman, who had undergone chemotherapy, partial excision of tumor followed by radiotherapy of sarcomatoid mesothelioma of the pleura, presented three months later with painless widespread subcutaneous nodules.
  • The subcutis is a particularly rare site of metastatic sarcomatoid mesothelioma.
  • It is essential to differentiate neoplasm metastatic to the skin and subcutis from primary and benign lesions of the same region.
  • FNAC is accurate and efficient, in conjugation with clinical history, and it also prevents surgical biopsy in the diagnosis of metastatic subcutaneous lesion.
  • To our knowledge, this is the first case, reported till date, in which the sarcomatoid mesothelioma metastasized to the subcutaneous tissue and was diagnosed by fine needle aspiration cytology (FNAC).
  • [MeSH-major] Mesothelioma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Pleural Neoplasms. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Subcutaneous Tissue

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366102.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


12. Yilmaz U, Polat G, Sahin N, Soy O, Gülay U: CT in differential diagnosis of benign and malignant pleural disease. Monaldi Arch Chest Dis; 2005 Mar;63(1):17-22
MedlinePlus Health Information. consumer health - Pleural Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT in differential diagnosis of benign and malignant pleural disease.
  • BACKGROUND: CT plays a valuable role in assessment of patients with a wide variety of diseases of the pleura, and pulmonologists should be aware of the significance of different CT findings for the differential diagnosis of benign and malignant pleural diseases.
  • METHODS: 155 patients with pleural disease who had undergone CT scans of the lungs and thorax before treatment were enrolled.
  • We retrospectively reviewed CT findings in 146 patients with proven pleural disease.
  • RESULTS: Fifty-nine of the cases were malignant, 87 of them had benign pleural diseases.
  • CT findings that were helpful in distinguishing malignant from benign pleural disease were:.
  • 1) pleural nodularity;. 2) rind;.
  • 3) mediastinal pleural involvement; and 4) pleural thickening greater than 1 cm.
  • CT findings differentiating malignant pleural mesothelioma from metastatic pleural disease were identified.
  • Findings for malignant mesothelioma were as follows:.
  • 1) involvement of interlobar fissure (sensitivity 30%, specificity 92%), 2) pleural thickening greater than 1 cm (sensitivity 60%, specificity 77%).
  • Whereas, findings for metastatic pleural disease were mediastinal/hilar lymph node enlargement and lung parenchymal involvement (P < .05).
  • CONCLUSION: CT is helpful in the differential diagnosis of pleural diseases, particularly in differentiating malignant from benign conditions and metastatic pleural disease from malignant mesothelioma.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035560.001).
  • [ISSN] 1122-0643
  • [Journal-full-title] Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
  • [ISO-abbreviation] Monaldi Arch Chest Dis
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Deniz H, Kibar Y, Güldür ME, Bakir K: Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Pathol Res Pract; 2009;205(11):749-52
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
  • Since pulmonary adenocarcinomas, malignant mesotheliomas (MM), and sometimes benign mesothelial proliferations show a great histomorphological resemblance to each other, an immunohistochemical panel is usually necessary for differential diagnosis.
  • It has also been suggested to be useful in identifying the mesothelial differentiation.
  • The aim of this study is to compare D2-40 immunostaining in MM, pulmonary adenocarcinoma, and benign mesothelial proliferations.
  • In this retrospective study, D2-40 immunostaining was investigated in 37 cases of MM, 36 cases of pulmonary adenocarcinoma, and 31 cases of benign mesothelial proliferation.
  • The diagnosis of MM had previously been confirmed by a panel including calretinin, CK5/6, and CEA.
  • Predominantly membranous immunoreactivity was observed in 51% of MMs and in 55% of benign mesothelial proliferations.
  • We believe that D2-40 may be helpful in the differential diagnosis of MM from pleural involvement of pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antibodies, Monoclonal. Lung / metabolism. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Solitary Fibrous Tumor, Pleural / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Biomarkers, Tumor / metabolism. Chi-Square Distribution. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Pleura / metabolism. Pleural Neoplasms / diagnosis. Pleural Neoplasms / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19573998.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


14. Haga T, Nakajima Y, Kitamura A, Kuroda F, Takiguchi Y, Tatsumi K: [Case of benign asbestos pleurisy with diffuse pleural thickening confirmed on autopsy]. Nihon Kokyuki Gakkai Zasshi; 2010 Nov;48(11):821-4
MedlinePlus Health Information. consumer health - Pleural Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of benign asbestos pleurisy with diffuse pleural thickening confirmed on autopsy].
  • Bilateral pleural effusion was revealed on a chest x-ray film.
  • Chest CT revealed diffuse thickening of the pleura, bilateral pleural effusions and cardiac effusion, but no abnormal findings in the lung fields.
  • Both pleural effusions were exudative, and lymphocytes were predominant.
  • Thoracoscopic pleural biopsy was conducted to exclude malignant mesothelioma.
  • No evidence of malignancy was found in pleural samples.
  • The patient's condition was diagnosed as benign asbestos pleurisy with diffuse pleural thickening.
  • Bilateral pleural effusions continued to progress despite pleurodesis and frequent drainage of his pleural effusion.
  • We investigated the concentration of asbestos bodies in his lung tissue.
  • There were 462 asbestos bodies per 1 g of dry lung tissue, which was relatively low considering the time of asbestos exposure.
  • We report a rare case of benign asbestos pleurisy with diffuse pleural thickening confirmed by autopsy.
  • [MeSH-major] Asbestosis / pathology. Autopsy. Pleura / pathology. Pleural Diseases / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Male. Occupational Exposure. Pleural Effusion / diagnosis. Pleural Effusion / pathology. Respiratory Insufficiency / etiology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21141060.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Yildirim H, Metintas M, Entok E, Ak G, Ak I, Dundar E, Erginel S: Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol; 2009 Dec;4(12):1480-4
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
  • BACKGROUND: Several studies have already addressed the potential role of an increased fluorine 18 fluorodeoxyglucose (18F FDG) uptake in identification of pleural malignancy.
  • In this pilot study, we investigate the role of 18F-FDG positron emission tomography/computed tomography (PET/CT) for differentiating asbestos-related benign pleural disease from malignant mesothelioma.
  • MATERIALS AND METHODS: The study population comprised 31 consecutive patients (17 malignant mesotheliomas, nine benign asbestos pleurisies, and five diffuse pleural fibrosis) with a mean age of 61 years between January 2006 and December 2008.
  • Thoracoscopy or image-guided pleural needle biopsy were systematically performed to reveal pathologic diagnosis and/or clinical follow-up for at least 3 years for presence or absence of malignant pleural effusion.
  • ROCs analyses for standardized uptake value (SUV) adjusted to body weight were calculated between benign and malignant pleural diseases.
  • RESULTS: 18F-FDG PET/CT imaging correctly detected the presence of malignancies in 15 of 17 patients with malignant mesothelioma for sensitivity, specificity, and overall accuracy of 88.2%, 92.9%, and 90.3%, respectively.
  • 18F-FDG PET/CT imaging correctly identified 13 of 14 cases of benign pleural disease.
  • The mean SUV values were 6.5 +/- 3.4 for malignant mesothelioma cases and 0.8 +/- 0.6 for benign pleural diseases (p < 0.001).
  • When we compared the two groups of pleural disease, a cut-off value of 2.2 for SUV gave the best accuracy with 94.1%, 100%, 100%, and 93.3% for sensitivity, specificity, positive predictive value, and negative predictive value, respectively.
  • CONCLUSION: Preliminary results of this trial provide evidence that 18F-FDG PET/CT imaging is a highly accurate and reliable noninvasive test to decide for further investigation of differentiating malignant mesothelioma from benign pleural disease.
  • [MeSH-major] Asbestos / adverse effects. Fluorodeoxyglucose F18. Mesothelioma / radionuclide imaging. Pleural Diseases / radionuclide imaging. Pleural Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinogens / pharmacology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pilot Projects. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875971.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 1332-21-4 / Asbestos
  •  go-up   go-down


16. Morokawa N, Takayanagi N, Ubukata M, Kurashima K, Yoned K, Tsuchiy N, Miyahara Y, Yamaguchi S, Tokunaga D, Saito H, Yanagisawa T, Sugita Y, Kawabata Y: [Autopsy case of diffuse pleural thickening presenting respiratory impairment and benign asbestos pleurisy]. Nihon Kokyuki Gakkai Zasshi; 2008 May;46(5):368-73
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of diffuse pleural thickening presenting respiratory impairment and benign asbestos pleurisy].
  • His chest CT showed bilateral pleural thickening and pleural effusion.
  • The pleural effusion of the right thorax exhibited both elevated level of adenosine deaminase and increased numbers of lymphocytes.
  • Progressive bilateral pleural thickening were found on chest CT, and pulmonary function tests showed severe restrictive ventilatory impairments since 1998.
  • Thoracoscopic pleural biopsy was conducted in 2001 to exclude pleural malignant mesothelioma.
  • No malignancy was found in pleural samples.
  • After 3-year observation and excluding other causes, he was given a diagnosis of benign asbestos pleurisy.
  • We suspected that diffuse pleural thickening could be a major cause of fatal respiratory impairment in this case.
  • [MeSH-major] Asbestos / adverse effects. Occupational Diseases / etiology. Occupational Diseases / pathology. Occupational Exposure / adverse effects. Pleura / pathology. Pleurisy / etiology. Pleurisy / pathology. Respiratory Insufficiency / etiology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18517012.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


17. Kradin RL, Mark EJ: Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach. Semin Diagn Pathol; 2006 Feb;23(1):4-14
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach.
  • This paper examines the spectrum of challenges that confront the diagnostic surgical pathologist in distinguishing benign mesothelial hyperplasia from malignant mesothelioma.
  • The current state of the art with respect to the morphological, immunohistological, and molecular features that can assist in the evaluation of benign and malignant pleural disease is examined.
  • [MeSH-major] Epithelium / pathology. Mesothelioma / diagnosis. Pleura / pathology. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Hyperplasia. Immunohistochemistry. Pleural Diseases / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044190.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


18. Granville L, Laga AC, Allen TC, Dishop M, Roggli VL, Churg A, Zander DS, Cagle PT: Review and update of uncommon primary pleural tumors: a practical approach to diagnosis. Arch Pathol Lab Med; 2005 Nov;129(11):1428-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review and update of uncommon primary pleural tumors: a practical approach to diagnosis.
  • OBJECTIVE: We address the current classifications and new changes regarding uncommon primary pleural tumors.
  • Primary pleural tumors are divided according to their behavior and are discussed separately as benign tumors, tumors of low malignant potential, and malignant neoplasms.
  • DATA SOURCES: Current literature concerning primary pleural neoplasms was collected and reviewed.
  • STUDY SELECTION: Studies emphasizing clinical, radiological, or pathologic findings of primary pleural neoplasms were obtained.
  • DATA EXTRACTION: Data deemed helpful to the general surgical pathologist when confronted with an uncommon primary pleural tumor was included in this review.
  • (1) benign, (2) low malignant potential, and (3) malignant.
  • A practical approach to the diagnosis of these neoplasms in surgical pathology specimens is offered.
  • The differential diagnosis, including metastatic pleural neoplasms, is also briefly addressed.
  • CONCLUSIONS: Uncommon primary pleural neoplasms may mimic each other, as well as mimic metastatic cancers to the pleura and diffuse malignant mesothelioma.
  • Correct diagnosis is important because of different prognosis and treatment implications for the various neoplasms.
  • [MeSH-major] Medical Oncology / methods. Mesothelioma / pathology. Neoplasm Metastasis / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Pleura / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253024.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Review
  • [Publication-country] United States
  • [Number-of-references] 131
  •  go-up   go-down


19. Cabay RJ, Siddiqui NH, Alam S: Paratesticular papillary mesothelioma: a case with borderline features. Arch Pathol Lab Med; 2006 Jan;130(1):90-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular papillary mesothelioma: a case with borderline features.
  • Most often, mesotheliomas involve the serosal (serous) membranes of the pleura and peritoneum.
  • Sometimes, mesothelial proliferations are identified in other locations.
  • On very rare occasions, a mesothelioma is found within the tunica vaginalis of the paratesticular region.
  • We report a case of papillary mesothelioma of the tunica vaginalis in a 52-year-old man.
  • Although this lesion had papillary structures lined by a single layer of mesothelial cells with predominantly bland nuclear and cytologic features, there was evidence of a minimal presence of mesothelial cells in the underlying stroma.
  • This combination of benign and semimalignant characteristics can make the diagnosis of such a lesion problematic.
  • We think that a diagnosis of "borderline papillary mesothelioma" can be considered for similar mesothelial proliferations to allow for a possible increase in diagnostic accuracy and provide an enhanced informational platform from which patients and clinicians can benefit.
  • [MeSH-major] Mesothelioma / pathology. Peritoneal Neoplasms / pathology. Testicular Neoplasms / pathology. Testis / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Disease-Free Survival. Humans. Immunohistochemistry. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16390245.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Liubchenko PN, Viatkina EI, Dubrova SE: [Case of asbestosis with massive benign pleural involvement]. Med Tr Prom Ekol; 2007;(4):35-9
MedlinePlus Health Information. consumer health - Pleural Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of asbestosis with massive benign pleural involvement].
  • Nodular masses in pleura revealed on pulmonary CT scans were considered as malignant mesothelioma.
  • For diagnosis verification, videothoracoscopy with target biopsy of the nodes was performed.
  • Histologic diagnosis - fragments of dense fibrous connective tissue.
  • FINAL DIAGNOSIS: Asbestosis, s/s, p/p, 2/2.
  • Pleural asbestosis.
  • [MeSH-major] Asbestosis / diagnosis. Pleural Diseases / diagnosis. Thoracoscopy / methods

  • Genetic Alliance. consumer health - Asbestosis.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17663051.001).
  • [ISSN] 1026-9428
  • [Journal-full-title] Meditsina truda i promyshlennaia ekologiia
  • [ISO-abbreviation] Med Tr Prom Ekol
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


21. Guinee DG, Allen TC: Primary pleural neoplasia: entities other than diffuse malignant mesothelioma. Arch Pathol Lab Med; 2008 Jul;132(7):1149-70
Genetic Alliance. consumer health - Mesothelioma, malignant.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pleural neoplasia: entities other than diffuse malignant mesothelioma.
  • CONTEXT: Overwhelmingly, the most common neoplasm involving the pleura is metastatic carcinoma.
  • In contrast, diffuse malignant mesothelioma occurs relatively rarely; however, it is nonetheless the most common neoplasm primary to the pleura.
  • Metastatic carcinoma and diffuse malignant mesothelioma each have their own prognostic and therapeutic characteristics.
  • Other primary pleural neoplasms occur uncommonly or rarely, with their own prognostic and therapeutic characteristics.
  • OBJECTIVE: To review primary pleural neoplasms other than diffuse malignant mesothelioma, to better ensure correct diagnosis and optimal assessment of prognosis and treatment.
  • CONCLUSIONS: A nonexhaustive group of uncommon to rare benign and malignant primary pleural neoplasms--other than diffuse malignant mesothelioma--are presented, of which one must be aware in order to maintain an appropriate index of suspicion to include them in the differential diagnosis of a pleural tumor.
  • [MeSH-major] Pleural Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18605768.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 244
  •  go-up   go-down


22. Meignan M, Paone G: [18-Fluoro-deoxy-glucose (15FDG) positon emission tomography (PET) for the evaluation of malignant pleural disease]. Rev Pneumol Clin; 2006 Apr;62(2):128-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18-Fluoro-deoxy-glucose (15FDG) positon emission tomography (PET) for the evaluation of malignant pleural disease].
  • [Transliterated title] La tomographie par émission de positons (TEP) au 18-fluoro-déoxy-glucose (18FDG) dans l'évaluation de la pathologie pleurale maligne.
  • Use of 18FDG-PET for malignant tumors of the pleura raises certain technical difficulties because of the small size of the tumors and their diffuse distribution, but hybrid PET/CT machines offer a better localization of FDG uptake.
  • FDG-PET can discriminate between malignant and benign pleural tumors FDG uptake in the pleura is the best diagnostic criteria of malignancy.
  • The presence of FDG uptake in pleural effusion is less discriminate between benign and malignant disease.
  • For mesotheliomas, FDG-PET can difference malignant tumors from benign tumors of the pleura on the basis of the SUV value (<or > 2).
  • SUV<4 associated with an epithelial tumor is a sign of good prognosis at three years.
  • SUV > 4 associated with a non-epithelial tumor is a sign of poor prognosis.
  • [MeSH-major] Fluorodeoxyglucose F18. Pleural Neoplasms / diagnosis. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Humans. Mesothelioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670667.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 19
  •  go-up   go-down


23. Stević R, Jovanović D, Mandarić M, Pesut D, Masulović D, Stosić-Opinćal T, Adzić T, Vasić N: [Radiologic manifestation of primary pleural tumors]. Acta Chir Iugosl; 2009;56(4):63-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiologic manifestation of primary pleural tumors].
  • OBJECTIVES: To show the radiological manifestations of primary pleural tumors.
  • PATIENTS AND METHODS: we carried out a retrospective analysis of radiological findings in 62 patients with primary malignant tumor of pleura.
  • Malignant tumors were present in 92.7% of the patients and benign ones in 7.2%.
  • The most common malignant tumor was mesothelioma (85.4%), and solitary fibrous tumor prevailed among benign tumors (9.7%).
  • Diffuse malignant mesothelioma manifested on computed tomography (CT) as a pleural thickening and effusion in 67.4% of the patients, tumors and effusion in 11.7%, and only as an effusion in 9.8% cases.
  • Thickening of the pleura appeared diffuse in 54% of patients and most often it had nodular pattern.
  • Both localized malignant and all benign tumors presented as tumor-like changes with the signs of necrosis in 50%.
  • CONCLUSION: The imaging methods have a key role in the diagnosis of pleural tumors.
  • CT shows different morphologic features of pleural lesions that have been established as a useful tool for differentiating malignant from benign disease.
  • However, magnetic resonance is preferred imaging method for assessing the extent and resectability of pleural tumors.
  • [MeSH-major] Pleural Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Mesothelioma / radiography. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20419999.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


24. Miles SE, Sandrini A, Johnson AR, Yates DH: Clinical consequences of asbestos-related diffuse pleural thickening: A review. J Occup Med Toxicol; 2008;3:20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical consequences of asbestos-related diffuse pleural thickening: A review.
  • Asbestos-related diffuse pleural thickening (DPT), or extensive fibrosis of the visceral pleura secondary to asbestos exposure, is increasingly common due to the large number of workers previously exposed to asbestos.
  • It may coexist with asbestos related pleural plaques but has a distinctly different pathology.
  • The pathogenesis of this condition as distinct from pleural plaques is gradually becoming understood.
  • Benign asbestos related pleural effusions commonly antedate the development of diffuse pleural thickening.
  • Environmental as well as occupational exposure to asbestos may also result in pleural fibrosis, particularly in geographic areas with naturally occurring asbestiform soil minerals.
  • Pleural disorders may also occur after household exposure.
  • High resolution computed tomography (CT) is more sensitive and specific than chest radiography for the diagnosis of diffuse pleural thickening, and several classification systems for asbestos-related disorders have been devised.
  • Magnetic resonance imaging and fluorodeoxyglucose positron emission tomography (PET) scanning may be useful in distinguishing between DPT and malignant mesothelioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Rev Respir Dis. 1987 Dec;136(6):1429-34 [2825569.001]
  • [Cites] Radiographics. 1989 May;9(3):523-51 [2727359.001]
  • [Cites] AJR Am J Roentgenol. 1988 Nov;151(5):883-91 [3263018.001]
  • [Cites] Br J Ind Med. 1988 Jul;45(7):443-9 [3260799.001]
  • [Cites] Occup Med. 1987 Apr-Jun;2(2):383-407 [3303386.001]
  • [Cites] Am Rev Respir Dis. 1984 Nov;130(5):884-7 [6497167.001]
  • [Cites] Eur J Respir Dis. 1987 Aug;71(2):113-21 [3622660.001]
  • [Cites] AJR Am J Roentgenol. 1985 Jan;144(1):9-18 [3871154.001]
  • [Cites] Ann Occup Hyg. 1985;29(3):305-55 [4073702.001]
  • [Cites] AJR Am J Roentgenol. 1990 Mar;154(3):487-92 [2106209.001]
  • [Cites] Respir Med. 1990 Mar;84(2):129-34 [2371434.001]
  • [Cites] Ann Occup Hyg. 1984;28(1):1-12 [6326648.001]
  • [Cites] Occup Environ Med. 2007 Nov;64(11):747-52 [17449562.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Oct;132(4):763-8 [17000285.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jun;129(6):1364-70 [15942579.001]
  • [Cites] Respirology. 2004 Nov;9(4):441-7 [15612954.001]
  • [Cites] Occup Environ Med. 2003 Jan;60(1):35-41; discussion 41-2 [12499455.001]
  • [Cites] Int Arch Occup Environ Health. 2002 Apr;75(4):224-8 [11981655.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):26-35 [11836666.001]
  • [Cites] Chin Med J (Engl). 2001 Jun;114(6):645-9 [11780445.001]
  • [Cites] Respiration. 2001;68(5):533-6 [11694819.001]
  • [Cites] Scand J Work Environ Health. 2001 Apr;27(2):154-5 [11409599.001]
  • [Cites] Radiology. 2001 Jul;220(1):237-43 [11426004.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Mar;163(3 Pt 1):640-4 [11254517.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Nov;162(5):1807-11 [11069817.001]
  • [Cites] Chest. 2000 Sep;118(3):604-9 [10988179.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Jul;162(1):98-104 [10903227.001]
  • [Cites] Clin Radiol. 2000 Jun;55(6):422-32 [10873686.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1507-15 [10556113.001]
  • [Cites] Respirology. 2004 Nov;9(4):428-40 [15612953.001]
  • [Cites] Chest. 2004 Dec;126(6):1994-9 [15596704.001]
  • [Cites] Thorax. 1999 Jul;54(7):638-52 [10377212.001]
  • [Cites] Chest. 1998 Sep;114(3):713-22 [9743156.001]
  • [Cites] Clin Chest Med. 1998 Jun;19(2):311-29 [9646983.001]
  • [Cites] Eur Respir J. 1998 May;11(5):1021-7 [9648950.001]
  • [Cites] J Clin Invest. 1998 Jul 15;102(2):445-54 [9664087.001]
  • [Cites] Am J Ind Med. 1996 Sep;30(3):241-51 [8876791.001]
  • [Cites] Thorax. 1996 Feb;51(2):210-6 [8711661.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Jan;153(1):301-6 [8542134.001]
  • [Cites] Occup Environ Med. 1994 Jul;51(7):456-60 [8044244.001]
  • [Cites] Chest. 1994 Jun;105(6):1748-52 [8205871.001]
  • [Cites] Br J Ind Med. 1993 Oct;50(10):902-6 [8217849.001]
  • [Cites] Eur Respir J. 1993 Jul;6(7):978-82 [8396536.001]
  • [Cites] Br J Ind Med. 1991 Nov;48(11):762-70 [1659443.001]
  • [Cites] Am Rev Respir Dis. 1991 Feb;143(2):408-22 [1990961.001]
  • [Cites] Chest. 1991 Jan;99(1):191-8 [1984952.001]
  • [Cites] Am Rev Respir Dis. 1990 Oct;142(4):837-42 [2221591.001]
  • [Cites] Br J Dis Chest. 1983 Oct;77(4):321-43 [6357260.001]
  • [Cites] Am J Med. 1983 Dec;75(6):911-9 [6650544.001]
  • [Cites] Eur J Respir Dis. 1980 Jun;61(3):129-38 [7002573.001]
  • [Cites] JAMA. 1982 Feb 5;247(5):617-22 [7054563.001]
  • [Cites] IARC Sci Publ. 1980;(30):237-46 [7239642.001]
  • [Cites] Thorax. 1980 Aug;35(8):564-9 [7444823.001]
  • [Cites] Thorax. 1980 Jan;35(1):31-6 [7361282.001]
  • [Cites] Chest. 1973 Aug;64(2):193-6 [4725075.001]
  • [Cites] Ann N Y Acad Sci. 1965 Dec 31;132(1):351-67 [5219560.001]
  • [Cites] Br J Dis Chest. 1966 Jan;60(1):19-22 [5920504.001]
  • [Cites] Radiology. 2004 Oct;233(1):182-90 [15333769.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Sep 15;170(6):691-715 [15355871.001]
  • [Cites] Invest Radiol. 2004 Sep;39(9):554-64 [15308938.001]
  • [Cites] Chest. 2004 Mar;125(3):1103-17 [15006974.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Jul;126(1):11-6 [12878934.001]
  • [Cites] Scand J Work Environ Health. 2003 Feb;29(1):60-3 [12630437.001]
  • (PMID = 18775081.001).
  • [ISSN] 1745-6673
  • [Journal-full-title] Journal of occupational medicine and toxicology (London, England)
  • [ISO-abbreviation] J Occup Med Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2553409
  •  go-up   go-down


25. Kayser K, Hoshang SA, Metze K, Goldmann T, Vollmer E, Radziszowski D, Kosjerina Z, Mireskandari M, Kayser G: Texture- and object-related automated information analysis in histological still images of various organs. Anal Quant Cytol Histol; 2008 Dec;30(6):323-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS: A generalized algorithm was developed that permits the evaluation of diagnosis-associated image features obtained from hematoxylin-eosin-stained histopathologic slides.
  • The procedure was tested for screening of tumor tissue vs. tumor-free tissue in 1,442 cases of various organs.
  • Tissue samples studied include colon, lung, breast, pleura, stomach and thyroid.
  • RESULTS: The accuracy of automated crude classification was between 95% and 100% based upon a learning set of 10 cases per diagnosis class.
  • The algorithm can also distinguish between benign and malignant tumors of colon, between epithelial mesothelioma and pleural carcinomatosis or between different common pulmonary carcinomas.
  • It is a promising technique that can assist tissue-based diagnosis and be expanded to virtual slide evaluation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160697.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Kurata S, Ishibashi M, Azuma K, Kaida H, Takamori S, Fujimoto K, Kobayashi M, Hirose Y, Aizawa H, Hayabuchi N: Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease. Jpn J Radiol; 2010 Jul;28(6):446-52
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease.
  • PURPOSE: The aim of this study was to compare the results of semiquantitative analysis by(18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) with plasma osteopontin levels in the same asbestos-related pleural disease population.
  • MATERIALS AND METHODS: A total of 17 patients with asbestos-related pleural disease were prospectively recruited.
  • The maximum standardized uptake value (SUVmax) was determined from the most active pleural lesion in each patient.
  • RESULTS: Malignant pleural mesothelioma (MPM) was histologically proven in 6 patients, and 11 patients had proven benign asbestos-related pleural diseases (7 pleural plaques, 4 asbestos pleurisy).
  • Significant differences in SUVmax were found between patients with MPM and those with asbestos pleurisy (P = 0.031) and between patients with MPM and those with pleural plaques (P = 0.012).
  • A significant difference was found in the plasma osteopontin levels between patients with asbestos pleurisy and patients with pleural plaques (Bonferroni correction, P = 0.024).
  • The SUVmax in patients with benign asbestos-related diseases was statistically positively correlated with plasma osteopontin in the same group (Spearman's r = 0.75, P < 0.05).
  • CONCLUSION: PET/CT might be more helpful than plasma osteopontin for distinguishing benign asbestos-related pleural diseases from MPM, and the SUVmax in benign asbestos-related pleural diseases may reflect changes in pleural inflammation.
  • [MeSH-major] Asbestos / toxicity. Mesothelioma / radionuclide imaging. Osteopontin / blood. Pleural Diseases / radionuclide imaging. Positron-Emission Tomography / methods. Tomography, Spiral Computed / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Imaging, Three-Dimensional / methods. Male. Middle Aged. Pleura / radiography. Pleura / radionuclide imaging. Pleural Neoplasms / blood. Pleural Neoplasms / radionuclide imaging. Pleurisy / blood. Pleurisy / radionuclide imaging. Prospective Studies. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661695.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 106441-73-0 / Osteopontin; 1332-21-4 / Asbestos
  •  go-up   go-down


27. Hieckel HG, Hering KG: [Asbestos-related diseases of the thorax]. Radiologe; 2010 Jul;50(7):623-33; quiz 634
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Asbestos fibers can lead to pulmonary fibrosis, thickening of the pleura and malignancies.
  • Occupationally-derived asbestos-related diseases of the thorax are asbestosis, asbestos-related benign pleurisy and malignant pleural mesothelioma.
  • [MeSH-major] Asbestosis / diagnosis. Carcinoma, Bronchogenic / diagnosis. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Pleurisy / diagnosis

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pneumologie. 2003 Oct;57(10 ):576-84 [14569528.001]
  • [Cites] Eur Respir J. 1998 May;11(5):1021-7 [9648950.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jul;181(1):163-9 [12818850.001]
  • [Cites] Pneumologie. 2009 Nov;63(11):664-8 [19862671.001]
  • [Cites] J Thorac Oncol. 2009 May;4(5):620-8 [19357540.001]
  • [Cites] Pneumologie. 2009 Dec;63(12 ):726-32 [19937572.001]
  • [Cites] Radiologe. 2004 May;44(5):500-11 [15094995.001]
  • [Cites] Radiology. 2003 Dec;229(3):731-6 [14576443.001]
  • (PMID = 20521020.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


28. Chapman EA, Thomas PS, Yates DH: Breath analysis in asbestos-related disorders: a review of the literature and potential future applications. J Breath Res; 2010 Sep;4(3):034001
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several diseases occur due to asbestos exposure, including malignant tumours such as malignant mesothelioma of the pleura and lung cancer, which have a very poor prognosis.
  • Asbestos inhalation may also result in more benign conditions such as asbestosis (or pulmonary fibrosis due to asbestos), pleural plaques and pleural thickening.
  • [MeSH-major] Asbestos / analysis. Asbestosis / diagnosis

  • MedlinePlus Health Information. consumer health - Asbestos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21383477.001).
  • [ISSN] 1752-7163
  • [Journal-full-title] Journal of breath research
  • [ISO-abbreviation] J Breath Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 1332-21-4 / Asbestos
  •  go-up   go-down






Advertisement